AVEO Pharmaceuticals Inc. (AVEO)
Oncology Corporate Profile

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company’s management will present at several upcoming investment conferences.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma .

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 30th Annual Global Growth Conference on Thursday, August 12, 2010 at 8:30 a.m. at the InterContinental Hotel in Boston.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present at the Cancer Stem Cells & The Tumor Microenvironment Conference, part of IBC’s Drug Discovery & Development Week, on Monday, August 2, 2010 at 1:45 p.m. at the Hyatt Regency San Francisco Airport in San Francisco.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s second quarter ended June 30, 2010 will be released before the market opens on Thursday, July 29, 2010.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer summarizing the recent development of improved preclinical modeling approaches to cancer drug development.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000® Index, as part of the annual reconstitution of the entire Russell family of indexes that took place on June 25, 2010 following the close of the market.

[Indie Research] - Earlier this week we noted that Dendreon had given up all of its gains from the knee-jerk rally upon the FDA approval of the firm's Provenge prostate cancer vaccine back in April, and apparently we weren't the only ones who noticed.

[AP] - Aveo Pharmaceuticals Inc. said Thursday that European Union regulators have granted orphan drug status to tivozanib, a drug Aveo is developing as a treatment for kidney cancer.

[Business Wire] - CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[oxy]phenyl}-N'- urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency .

CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S.

CAMBRIDGE, Mass. & CHICAGO----AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival achieved by patients with advanced clear cell renal cell carcinoma who had undergone a prior nephrectomy was 14.8 months.